# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benny Leonard (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX008-SYN-TD
- Date: 1946-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Miriam Okafor-Rosenthal, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Twenty-four-week review: blood pressure, work, mood, worry and aspirin. **S**

## History of present illness

Mr. Leonard returns six months after intake. He has refereed full cards each week and taught his classes without breathlessness, chest tightness, palpitations or lightheadedness. His home readings over the past week averaged 120/76 mmHg. He takes losartan, amlodipine and atorvastatin every day; the ankle puffiness is slight. He feels less worried about money and sleeps better. He asked again about aspirin, which the cardiologist had raised. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 120/76 mmHg over seven days |
| Mood and worry | PHQ-9 2; GAD-7 3 |
| Work | Full cards weekly without symptoms |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest discomfort, palpitations, fainting or breathlessness at work |
| Gastrointestinal | Negative | No indigestion, black stools or bleeding |
| Psychiatric | Negative | Mood good; less worry; sleeping six to seven hours |

3 systems reviewed. **S**

## Current medications

- Atorvastatin 40 mg tablet, one each evening **S**
- Losartan 100 mg tablet, one each morning **S**
- Amlodipine 5 mg tablet, one each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 73 kg; BMI 26.8 kg/m². All vital signs are synthetic.

PHQ-9: 2; GAD-7: 3. All results are synthetic.

## Change since baseline

- PHQ-9: 5 at baseline, 2 at this visit **S**
- GAD-7: 6 at baseline, 3 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Recombinant zoster vaccine, dose 2 of 2 **S**
- Influenza vaccine, inactivated trivalent, this season's formulation **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/76 mmHg, pulse 66; weight 73.0 kg |
| Cardiovascular | Regular rhythm; no murmur; trace ankle edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertensive heart disease** (I11.9). Controlled for two months at below 130/80 mmHg at home and in the clinic, without symptoms at work. **S**
   - Continue losartan 100 mg and amlodipine 5 mg.
   - Repeat echocardiogram in about six months, a year after the first, to look for regression of the hypertrophy.
   - Basic metabolic panel and urine albumin-to-creatinine ratio in about four months.
2. **Coronary atherosclerosis (calcium score 186)** (I25.10). On atorvastatin with LDL at goal. Low-dose aspirin was discussed as a shared decision: with a calcium score over 100 and blood pressure now controlled it may be considered, but the expected benefit at his risk is small and it raises the risk of bleeding. He chose not to start it, and the decision will be revisited yearly or if his risk changes. **S**
   - No aspirin by his choice.
   - Lipid panel in about six months, a year after starting atorvastatin.
3. **Money worries and mood**. PHQ-9 2 and GAD-7 3, both down from intake; steadier work and affordable medicines. **S**
   - Repeat screens at the yearly visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 122/76 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Seven-day average 120/76 mmHg |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Up to date | Normal two months ago; next in about four months |
| Laboratory | Urine albumin-to-creatinine ratio | At diagnosis, then yearly | Up to date | Due a year after intake |
| Laboratory | HbA1c | At diagnosis, then yearly | Up to date | Due a year after intake |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | LDL 66 mg/dL; next a year after starting atorvastatin |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Due | Repeat in about six months, a year after the first |
| Imaging | Stress testing or coronary imaging | For new or changed exertional symptoms; not for routine surveillance | Not indicated | No symptoms; routine surveillance testing is not recommended |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | None |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 73.0 kg, BMI 26.8; brisk walks most mornings |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | No missed doses; trace ankle edema only |
| Medication safety | Aspirin decision | When risk changes | Completed today | Shared decision: not started, by his choice; revisit yearly |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Full cards weekly without symptoms |
| Survey | Depression screen (PHQ-9) | At intake, then yearly or with change | Completed today | 2, from 5; item 9 scored 0 |
| Survey | Anxiety screen (GAD-7) | At intake, then yearly or with change | Completed today | 3, from 6 |
| Self-management | Financial strain and medicine cost | Every visit | Completed today | Three generic medicines at low cost; money steadier |

## Goal progress

- Find the cause of the exertional breathlessness and chest tightness. Outcome by 1946-05-26: No inducible ischemia; symptoms from hypertensive heart disease with an exaggerated blood pressure response. **S**
- Blood pressure below 130/80 mmHg at home and in the clinic. Outcome by 1946-08-25: 164/100 at intake to 124/78 in the clinic, home average 122/76 mmHg. **S**
- LDL below 70 mg/dL and at least 50% lower than at intake. Outcome by 1946-07-28: LDL 160 to 66 mg/dL (59% lower) on atorvastatin 40 mg. **S**
- Keep refereeing full cards safely, without symptoms. In progress; target 1947-05-12. **S**
- Regression of left ventricular hypertrophy on a repeat echocardiogram. In progress; target 1947-05-26. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026), American College of Cardiology and American Heart Association (Circulation 2026;153(17):e1154-e1276)
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019), American College of Cardiology and American Heart Association (Circulation 2019;140(11):e596-e646)
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015), American Heart Association and American College of Cardiology (Circulation 2015;132(22):e298-e302)
- CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- Anxiety Disorders in Adults: Screening (2023), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Second hepatitis B and zoster doses and the influenza vaccine today; COVID-19 vaccine at the pharmacy. Basic metabolic panel and urine albumin in about four months. Echocardiogram and lipid panel in about six months. Next preventive visit in July. **S**

